Cohort- and time-specific associations of CTLA4 genotypes with HIV-1 disease progression

AIDS

Volumn 20, Issue 12, 2006, Pages 1583-1590

  Shao, Wenshuo ^a   Lazaryan, Aleksandr ^a   Dorak, M Tevfik ^a   Penman Aguilar, Ana ^a   Wilson, Craig M ^b,c   Margolick, Joseph B ^d   Goedert, James J ^e   Prins, Maria ^f   Tang, Jianming ^c   Kaslow, Richard A ^a,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f Public Health Laboratory   (Netherlands)

Author keywords

AIDS; CTLA4; Genetics; HIV; Virus load

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA ANTIGEN CLASS 1;

3' UNTRANSLATED REGION; ADOLESCENT; ADULT; ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 GENE; DISEASE ASSOCIATION; DISEASE COURSE; ETHNOLOGY; FEMALE; GENE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SEROCONVERSION; SEX RATIO; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GENOTYPE; HAPLOTYPES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; VIRAL LOAD;

EID: 33746777841     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000238403.08497.3f     Document Type: Article

References (49)

1. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-mediated inhibition of early events of T cell proliferation. J Immunol 1999; 162:5813-5820.
2. Chambers CA, Allison JP. Costimulatory regulation of T cell function. Curr Opin Cell Biol 1999; 11:203-210.
3. Chambers CA, Kuhns MS, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. Proc Natl Acad Sci USA 1999; 96:8603-8608.
4. Carreno BM, Bennett F, Chau TA, Ling V, Luxenberg D, Jussif J, Baroja ML, Madrenas J, et al. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J Immunol 2000; 165:1352-1356.
5. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994, 1:793-801 [published erratum appears in Immunity 1995 2(2):203].
6. Riley JL, Schlienger K, Blair PJ, Carreno B, Craighead N, Kim D, Carroll RG, June CH, et al. Modulation of susceptibility to HIV-1 infection by the cytotoxic T lymphocyte antigen 4 costimulatory molecule. J Exp Med 2000; 191:1987-1997.
7. Leng Q, Bentwich Z, Magen E, Kalinkovich A, Borkow G. CTLA-4 upregulation during HIV infection: association with anergy and possible target for therapeutic intervention. AIDS 2002; 16:519-529.
8. Ligers A, Teleshova N, Masterman T, Huang WX, Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2001; 2:145-152.
9. Maurer M, Loserth S, Kolb-Maurer A, Ponath A, Wiese S, Kruse N, Rieckmann P, et al. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 2002; 54:1-8.
10. Wang XB, Zhao X, Giscombe R, Lefvert AK. A CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein. Genes Immun 2002; 3:233-234.
11. Harbo HF, Celius EG, Vartdal F, Spurkland A. CTLA4 promoter and exon 1 dimorphisms in multiple sclerosis. Tissue Antigens 1999; 53:106-110.
12. Howard TD, Postma DS, Hawkins GA, Koppelman GH, Zheng SL, Wysong AK, et al. Fine mapping of an IgE-controlling gene on chromosome 2q: Analysis of CTLA4 and CD28. J Allergy Clin Immunol 2002; 110:743-751.
13. King AL, Moodie SJ, Fraser JS, Curtis D, Reid E, Dearlove AM, et al. Coeliac disease: investigation of proposed causal variants in the CTLA4 gene region. Eur J Immunogenet 2003; 30:427-432.
14. Barton A, Jury F, Eyre S, Bowes J, Hinks A, Ward D, et al. Haplotype analysis in simplex families and novel analytic approaches in a case-control cohort reveal no evidence of association of the CTLA-4 gene with rheumatoid arthritis. Arthritis Rheum 2004; 50:748-752.
15. Holopainen PM, Partanen JA. Technical note: linkage disequilibrium and disease-associated CTLA4 gene polymorphisms. J Immunol 2001; 167:2457-2458.
16. Kaur G, Sachdeva G, Bhutani LK, Bamezai R. Association of polymorphism at COL3A and CTLA4 loci on chromosome 2q31-33 with the clinical phenotype and in-vitro CMI status in healthy and leprosy subjects: a preliminary study. Hum Genet 1997; 100:43-50.
17. Heinzmann A, Plesnar C, Kuehr J, Forster J, Deichmann KA. Common polymorphisms in the CTLA-4 and CD28 genes at 2q33 are not associated with asthma or atopy. Eur J Immunogenet 2000; 27:57-61.
18. Ling V, Wu PW, Finnerty HF, Agostino MJ, Graham JR, Chen S, et al. Assembly and annotation of human chromosome 2q33 sequence containing the CD28, CTLA4, and ICOS gene cluster: analysis by computational, comparative, and microarray approaches. Genomics 2001; 78:155-168.
19. Kouki T, Gardine CA, Yanagawa T, Degroot LJ. Relation of three polymorphisms of the CTLA-4 gene in patients with Graves' disease. J Endocrinol Invest 2002; 25:208-213.
20. Kouki T, Sawai Y, Gardine CA, Fisfalen M-E, Alegre M-L, DeGroot LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000; 165:6601-6611.
21. Kristiansen OP, Larsen ZM, Pociot F. CTLA-4 in autoimmune diseases - a general susceptibility gene to autoimmunity? Genes Immun 2000; 1:170-184.
22. Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology 2000; 31:49-53.
23. Marron MP, Raffel LJ, Garchon HJ, Jacob CO, Serrano-Rios M, Martinez Larrad MT, et al. Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Hum Mol Genet 1997; 6:1275-1282.
24. Larsen ZM, Kristiansen OP, Mato E, Johannesen J, Puig-Domingo M, de Leiva A, et al. IDDM12 (CTLA4) on 2q33 and IDDM13 on 2q34 in genetic susceptibility to type 1 diabetes (insulin-dependent). Autoimmunity 1999; 31:35-42.
25. Agarwal K, Jones DE, Daly AK, James OF, Vaidya B, Pearce S, et al. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J Hepatol 2000; 32:538-541.
26. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423:506-511.
27. Yee LJ, Perez KA, Tang J, van Leeuwen DJ, Kaslow RA. Association of CTLA4 gene variants with sustained response to interferon+ribavirin therapy for chronic Hepatitis C virus infection. J Infect Dis 2003; 187:1264-1271.
28. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987; 126:310-318.
29. Keet IP, Tang J, Klein MR, LeBlanc S, Enger C, Rivers C, et al. Consistent associations of HLA class I and class II and transporter gene products with progression of human immunodeficiency virus-1 infection in homosexual men. J Infect Dis 1999; 180:299-309.
30. Dorak MT, Tang J, Tang S, Penman-Aguilar A, Coutinho RA, et al. Influence of human leukocyte antigen-B22 alleles on the course of human immunodeficiency virus type 1 infection in 3 cohorts of white men. J Infect Dis 2003; 188:856-863.
31. Tang J, Shelton B, Makhatadze NJ, Zhang Y, Schaen M, Louie LG, et al. Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. J Virol 2002; 76:662-672.
32. Tang J, Wilson CM, Meleth S, Myracle A, Lobashevsky E, Mulligan MJ, et al. Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. AIDS 2002; 16:2275-2284.
33. Keet IP, Krijnen P, Koot M, Lange JM, Miedema F, Goudsmit J, et al. Predictors of rapid progression to AIDS in HIV-1 sero-converters. AIDS 1993; 7:51-57.
34. Goedert JJ, Biggar RJ, Winn DM, Mann DL, Byar DP, Strong DM, et al. Decreased helper T lymphocytes in homosexual men. I. Sexual contact in high-incidence areas for the acquired immunodeficiency syndrome. Am J Epidemiol 1985; 121:629-636.
35. Council of State and Territorial Epidemiologists and AIDS Program NCfID. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. 1987, 36 (Suppl):31S-15S.
36. Rogers AS, Futterman DK, Moscicki AB, Wilson CM, Ellenberg J, Vermund SH. The REACH Project of the Adolescent Medicine HIV/AIDS Research Network: design, methods, and selected characteristics of participants. J Adolesc Health 1998; 22:300-311.
37. Vermund SH, Wilson CM, Rogers AS, Partlow C, Moscicki AB. Sexually transmitted infections among HIV infected and HIV uninfected high-risk youth in the REACH study. Reaching for Excellence in Adolescent Care and Health. J Adolesc Health 2001; 29:49-56.
38. Tang J, Wilson CM, Schaen M, Myracle A, Douglas SD, Kaslow RA. CCR2 and CCR5 genotypes in HIV type 1-infected adolescents: limited contributions to variability in plasma HIV type 1 RNA concentration in the absence of antiretroviral therapy. AIDS Res Hum Retroviruses 2002; 18:403-412.
39. Rutter CM, Elashoff RM. Analysis of longitudinal data: random coefficient regression modelling. Stat Med 1994; 13:1211-1231.
40. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
41. Cox DR. Regression models and life-tables. J Roy Statist Soc 1972; 34:187-220.
42. Yeh FC, Boyle TJ. Population genetic analysis of co-dominant and dominant markers and quantitative traits [abstract]. Belg J Botany 1997; 129:157.
43. Mulherin SA, O'Brien TR, Ioannidis JP, Goedert JJ, Buchbinder SP, Coutinho RA, et al. Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS 2003; 17:377-387.
44. Tang J, Kaslow RA. The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy. AIDS 2003; 17 (Suppl 4):S51-S60.
45. Andersson J, Boasso A, Nilsson J, Zhang R, Shire NJ, Lindback S, et al. The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J Immunol 2005; 174:3143-3147.
46. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narvaez AB, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 2004; 104:942-947.
47. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996; 384:529-534.
48. Nkengasong JN, Kestens L, Ghys PD, Koblavi-Deme S, Bile C, Kalou M, et al. Human immunodeficiency virus Type 1 (HIV-1) plasma virus load and markers of immune activation among HIV-infected female sex workers with sexually transmitted diseases in Abidjan, Cote d'Ivoire. J Infect Dis 2001; 183:1405-1408.
49. Johnson GC, Esposito L, Barratt BJ, Smith AN, Heward J, Di Genova G, et al. Haplotype tagging for the identification of common disease genes. Nat Genet 2001; 29:233-237.